Method for activation of helper t cell and composition for use in the method

ABSTRACT

Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.

TECHNICAL FIELD

The present invention relates to a method for the activation of a helperT cell, comprising adding a WT1 peptide to an antigen-presenting cell,and thereby activating the helper T cell, wherein the WT1 peptide has anability to any one of an HLA-DRB1*1501 molecule, HLA-DPB1*0901 moleculeand HLA-DPB1*0501 molecule and a composition for the same, apharmaceutical composition for the treatment and/or prevention of acancer by activating a helper T cell and the like.

BACKGROUND

WT1 gene (Wilms' tumor 1 gene) was identified as a gene responsible forWilms tumor which is a renal cancer in children (Non-Patent Documents 1and 2). WT1 is a transcription factor having a zinc finger structure. Atthe beginning, the WT1 gene was considered to be a tumor suppressorgene. However, subsequent studies (Non-Patent Documents 3, 4, 5 and 6)showed that the WT1 gene rather functions as an oncogene inhematopoietic tumors and solid cancers.

It was shown that a WT1 peptide-specific T-lymphocyte (CTL) can beinduced by in vitro stimulating a peripheral blood mononuclear cell witha WT1 peptide, and such a CTL damages a cancer cell such as ahematopoietic tumor cell and solid cancer cell which endogenouslyexpresses WT1. The CTL recognizes the WT1 peptide as the form of thecomplex in which the WT1 peptide binds to an MHC class I molecule.Therefore, such a WT1 peptide is different depending on the subtypes ofMHC class I (Patent Document 1, Non-Patent Document 7, and PatentDocuments 2, 3 and 4).

The existence of a helper T cell specific for an cancer antigen isimportant to induce a CTL effectively (Non-Patent Document 8). Thehelper T cell is induced and activated by the recognition of a complexof an MHC class II molecule and an antigen peptide on anantigen-presenting cell. The activated helper T cell produces a cytokinesuch as IL-2, IL-4, IL-5, IL-6 or interferon to help the growth,differentiation or maturation of a B cell. The activated helper T cellalso has a function to facilitate the growth, differentiation ormaturation of other T cell subsets (for example, Tc and TD cell). Thus,the activated helper T cell has a function to activate an immune systemby facilitating the growth or activation of a B cell or T cell.Therefore, enhancing a function of a helper T cell through an MHC classII-binding antigen peptide (a helper peptide) in a cancer immunotherapyto increase the effect of a cancer vaccine is considered to be useful(Non-Patent Document 9). Only a peptide binding to an HLA-DRB1*0401molecule (Non-Patent Document 10), a peptide binding to an HLA-DRB1*0405molecule and a peptide binding to an HLA-DRB1*1502 molecule (PatentDocument 5) were found as a helper peptide of WT1 to date. Therefore,there is a need to find peptides each biding to an HLA-DRB1*1501,HLA-DPB1*0901 or HLA-DPB1*0501 molecule.

Furthermore, it was shown that among the helper peptides, there is apromiscuous helper peptide which can bind to multiple MHC class IImolecules, and induce helper T cells (Non-Patent Documents 11 and 12).However, it was very difficult to identify a promiscuous helper peptidewhich binds to three or more types of MHC class II molecules and exertsa sufficient effect.

Patent Document 1: WO 2003/106682

Patent Document 2: WO 2005/095598

Patent Document 3: WO 2007/097358

Patent Document 4: International Patent Application No.PCT/JP2007/074146

Patent Document 5: WO 2005/045027

Non-Patent Document 1: Daniel A. Haber et al., Cell. 1990 Jun. 29;61(7):1257-69.

Non-Patent Document 2: Call K M et al., Cell. 1990 Feb. 9; 60(3):509-20.

Non-Patent Document 3: Menke A L et al., Int Rev Cytol. 1998;181:151-212. Review.

Non-Patent Document 4: Yamagami T et al., Blood. 1996 Apr. 1;87(7):2878-84.

Non-Patent Document 5: Inoue K et al., Blood. 1998 Apr. 15;91(8):2969-76.

Non-Patent Document 6: Tsuboi A et al., Leuk Res. 1999 May;23(5):499-505.

Non-Patent Document 7: Oka Y et al., Immunogenetics. 2000 February;51(2):99-107.

Non-Patent Document 8: Gao F G et al., Cancer Res. 2002 Nov. 15;62(22):6438-41.

Non-Patent Document 9: Zeng G, J Immunother. 2001 May; 24(3):195-204

Non-Patent Document 10: Knights A J et al., Cancer Immunol Immunother.2002 July; 51(5):271-81.

Non-Patent Document 11: Sotiriadou R et al., Br J Cancer. 2001 Nov. 16;85(10):1527-34.

Non-Patent Document 12: Hural J A et al., J Immunol. 2002 Jul. 1;169(1):557-65.

DISCLOSURE OF INVENTION Problems to be Solved by the Invention

The problems to be solved by the present invention are to provide to amethod for the activation of a helper T cell with a WT1 peptide whichhas an ability to bind to an HLA-DRB1*1501 molecule, HLA-DPB1*0901molecule or HLA-DPB1*0501 molecule and a composition for the same, aswell as a pharmaceutical composition for the treatment and/or preventionof a cancer by activating a helper T cell and the like.

Means to Solve the Problems

As a result of intensive studies in view of the situation as describedabove, the present inventor has found that among WT1 peptides which bindto an HLA-DRB1*0405 molecule and HLA-DRB1*1502 molecule, a WT1 peptidehaving an amino acid sequence: Lys Arg Tyr Phe Lys Leu Ser His Leu GlnMet His Ser Arg Lys His also binds to an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule. Thus, the presentinvention has been completed.

The present invention provides:

(1) a method for the activation of a helper T cell, comprising adding aWt1 peptide to an antigen-presenting cell, and thereby activating thehelper T cell, wherein the WT1 peptide has an ability to bind to any oneof an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule;

(2) the method according to (1), wherein the WT1 peptide has an abilityto bind to at least two of an HLA-DRB1*1501 molecule, HLA-DPB1*0901molecule and HLA-DPB1*0501 molecule;

(3) the method according to (1) or (2), wherein the WT1 peptide furtherhas an ability to bind to an HLA-DRB1*0405 molecule and/or HLA-DRB1*1502molecule;

(4) the method according to any one of (1)-(3), wherein the WT1 peptidehas an ability to bind to an HLA-DRB1*1501 molecule, HLA-DPB1*0901molecule, HLA-DPB1*0501 molecule, HLA-DRB1*0405 molecule andHLA-DRB1*1502 molecule;

(5) the method according to any one of (1)-(4), wherein the WT1 peptideis a peptide comprising an amino acid sequence: Lys Arg Tyr Phe Lys LeuSer His Leu Gln Net His Ser Arg Lys His (SEQ ID No: 2);

(6) the method according to any one of (1)-(5), wherein the addition ofthe WT1 peptide to the antigen-presenting cell is practiced by theaddition of the WT1 peptide, the addition of n expression vectorcomprising the polynucleotide encoding the WT1 peptide or the additionof a cell including the expression vector;

(7) a composition for activating a helper T cell by the addition of aWT1 peptide to an antigen-presenting cell, comprising the WT1 peptide,wherein the WT1 peptide has an ability to bind to any one of anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule;

(8) a method for the treatment or prevention of a cancer in a subject,comprising adding a WT1 peptide to an antigen-presenting cell, andthereby activating a helper T cell, wherein the WT1 peptide has anability to bind to any one of an HLA-DRB1*1501 molecule, HLA-DPB1*0901molecule and HLA-DPB1*0501 molecule;

(9) a pharmaceutical composition for the treatment or prevention of acancer by activating a helper T cell by the addition of a WT1 peptide toan antigen-presenting cell, comprising the WT1 peptide, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule;

(10) an antibody binding specifically to a WT1 peptide, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule;

(11) a method for the determination of the presence or amount of a WT1peptide in any one of an HLA-DRB1*1501-positive, HLA-DPB1*0901-positiveand HLA-DPB1*0501-positive subject, comprising:

(a) reacting an anti-WT1 antibody with a sample from the subject; and(b) determining the presence or amount of the anti-WT1 antibody bindingspecifically to the WT1 peptide contained in the sample;

(12) a method for the treatment or prevention of a cancer, comprisingadding a WT1 peptide to an antigen-presenting cell, and therebyactivating a helper T cell, and administering the activated helper Tcell to a subject, wherein the WT1 peptide has an ability to bind to anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501molecule;

(13) a pharmaceutical composition for the treatment or prevention of acancer, comprising a helper T cell activated with a WT1 peptide, whereinthe WT1 peptide has an ability to bind to any one of an HLA-DRB1*1501molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule;

(14) a method for the determination of the presence or amount of aWT1-specific helper T cell in any one of an HLA-DRB1*1501-positive,HLA-DPB1*0901-positive and HLA-DPB1*0501-positive subject, comprising:

(a) reacting a complex of a WT1 peptide and an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule with a sample from thesubject; and(b) determining the presence or amount of a helper T cell recognizingthe complex contained in the sample; and

(15) a method for the determination of the presence or amount of aWT1-specific helper T cell in an HLA-DRB1*1501-positive,HLA-DPB1*0901-positive, HLA-DPB1*0501-positive, HLA-DRB1*0405-positiveor HLA-DRB1*1502-positive subject, comprising:

(a) stimulating a peripheral blood mononuclear cell, invasivelymphocyte, tumor cell, cell in ascitic fluid, cell in pleural fluid,cell in cerebrospinal fluid, bone marrow cell or lymph node cell with aWT1 peptide; and(b) determining the production of a cytokine or the reaction of thehelper T cell,wherein a presence or an increase in the amount of the production of thecytokine or the reaction of the helper T cell indicates the presence oramount of the WT1-specific helper T cell.

EFFECTS OF THE INVENTION

The present invention provides a method for the activation of a helper Tcell with a WT1 peptide which binds to an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule, HLA-DPB1*0501 molecule, HLA-DRB1*0405 molecule,and HLA-DRB1*1502 molecule and a composition for the same, as well as apharmaceutical composition for the treatment and/or prevention of acancer by activating a helper T cell, and the like. Therefore, it ispossible to activate in vivo and in vitro a helper T cell in the subjecthaving any of such MHC class II molecules, treat and prevent a cancerand the like. Because about 90% of Japanese people are covered by thefive types of MHC class II subclasses, helper T cells can be activatedto treat and/or prevent a cancer in a very wide range of subjects.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a graph which represents the amount of IFN-γ produced byTA28.1 cell. In the figure, a longitudinal axe represents concentrationof IFN-γ (pg/ml). The graphs correspond to “the case of culturingperipheral blood mononuclear cells from an HLA-DRB1*1501-positivesubject in the absence of the WT1 peptide”, “the case of culturingTA28.1 cells in the presence of the WT1 peptide (black)”, “the case ofculturing peripheral blood mononuclear cells from anHLA-DRB1*1501-negative subject in the absence of the WT1 peptide”, “thecase of culturing peripheral blood mononuclear cells from anHLA-DRB1*1501-negative subject in the presence of the WT1 peptide”starting from the left, respectively.

FIG. 2 is a graph which represents the amounts of IFN-γ, IL-4 and IL-10produced by TA28.1 cell. In the figure, a longitudinal axe representsconcentration (pg/ml). The graphs correspond the values of IFN-γ, IL-4and IL-10 starting from the left.

FIG. 3 is a graph which represents the amounts of IFN-γ, IL-4 and IL-10produced by E15.2 cell. In the figure, a longitudinal axe representsconcentration (pg/ml). The graphs correspond to the values of IFN-γ,IL-4 and IL-10 starting from the left.

FIG. 4 represents the productions of IFN-γ and IL-17 byHLA-DPB1*0501/*0501-positive mononuclear cells. In the figure, ahorizontal axe represents IFN-γ, and a longitudinal axe representsIL-17. FIG. 4 a represents the cells without stimulating with the WT1peptide, and FIG. 4 b represents the cells stimulated with the WT1peptide.

FIG. 5 is a graph which represents the growth of TA28.1 cells. In thefigure, a longitudinal axe represents cpm (×10⁴). The graphs correspondto “the case of coculturing TA28.1 cells with peripheral bloodmononuclear cells without pulsing with a WT1 peptide”, “the case ofcoculturing TA28.1 cells with peripheral blood mononuclear cells pulsedwith a WT1 peptide (black)”, “the case of culturing TA28.1 cells withperipheral blood mononuclear cells pulsed with a WT1 peptide in thepresence of an anti-MHC class I antibody”, “the case of coculturingTA28.1 cells with peripheral blood mononuclear cells pulsed with a WT1peptide in the presence of an anti-HLA-DR antibody (shaded)”, “the caseof coculturing TA28.1 cells with peripheral blood mononuclear cellspulsed with a WT1 peptide in the presence of an anti-HLA-DQ antibody”,“the case of coculturing TA28.1 cells with peripheral blood mononuclearcells pulsed with a WT1 peptide in the presence of ananti-HLA-Dantibody” starting from the left, respectively.

FIG. 6 is a graph which represents the growth of E15.2 cells. In thefigure, a longitudinal axe represents cpm (×10⁴). The graphs correspondto “the case of coculturing E15.2 cells with peripheral bloodmononuclear cells from an HLA-DPB1*0901-positive subject without pulsingwith a WT1 peptide”, “the case of coculturing E15.2 cells withperipheral blood mononuclear cells from an HLA-DPB1*0901-positivesubject pulsed with a WT1 peptide (black)”, “the cases of coculturingE15.2 cells with peripheral blood mononuclear cells from anHLA-DPB1*0901-negative subject without pulsing with a WT1 peptide”, “thecase of coculturing E15.2 cells with peripheral blood mononuclear cellsfrom an HLA-DPB1*0901-negative subject pulsed with a WT1 peptide”starting from the left, respectively.

FIG. 7 is a graph which represents the growth of E15.2 cells. In thefigure, a longitudinal axe represents cpm. The graphs correspond to “thecase of coculturing E15.2 cells with peripheral blood mononuclear cellswithout pulsing with a WT1 peptide”, “the case of coculturing E15.2cells with peripheral blood mononuclear cells pulsed with a WT1 peptide(black)”, “the case of coculturing E15.2 cells with peripheral bloodmononuclear cells pulsed with a WT1 peptide in the presence of ananti-MHC class I antibody”, “the case of coculturing E15.2 cells withperipheral blood mononuclear cells pulsed with a WT1 peptide in thepresence of an anti-HLA-DR antibody”, “the case of coculturing E15.2cells with peripheral blood mononuclear cells pulsed with a WT1 peptidein the presence of an anti-HLA-DQ antibody”, and “the case ofcoculturing E15.2 cells with peripheral blood mononuclear cells pulsedwith a WT1 peptide in the presence of an anti-HLA-DP antibody (shaded)”starting from the left, respectively.

FIG. 8 is a graph which represents the growth ofHLA-DPB1*0501/*0501-positive mononuclear cells. In the figure, alongitudinal axe represents cpm. The graphs correspond to “the casewithout stimulation with a WT1 peptide” and “the case with stimulationwith a WT1 peptide” starting from the left, respectively.

FIG. 9 represents that the growth of HLA-DPB1*0501/*0501-positivemononuclear cells is suppressed by anti-HLA-DP antibodies. In thefigure, a longitudinal axe represents cpm. The graphs correspond to “thecase without stimulation with a WT1 peptide”, “the case with stimulationwith a control peptide from HIV”, “the case with stimulation with a WT1peptide”, “the case with stimulation with a WT1 peptide in the presenceof an anti-HLA-DR antibody”, “the case with stimulation with a WT1peptide in the presence of an anti-HLA-DQ antibody” and “the case withstimulation with a WT1 peptide in the presence of an anti-HLA-Dantibody”starting from the left, respectively.

FIG. 10 is a graph which represents the growth of E15.2 cell in thecases of using various concentration of a WT1 peptide. In the figure, alongitudinal axe represents cpm (×10⁴), and a horizontal axe representsthe concentration of the WT1 peptide.

BEST MODE FOR CARRYING OUT THE INVENTION

In one aspect, the present invention relates to a method for theactivation of a helper T cell, comprising adding a WT1 peptide to anantigen-presenting cell, and thereby activating the helper T cell,wherein the WT1 peptide has an ability to bind to any one of anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule. In the present invention, the WT1 peptide refers a peptideconsisting of a part of the amino acid sequence of human WT1 proteinshown in SEQ ID No: 1, a peptide which has a substitution, modification,or deletion of one to several amino acids in the amino acid sequence,and has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule, or a peptide in whichvarious substances such as an amino acid, a peptide or an analog thereofmay be attached at the N-terminus and/or the C-terminus of the peptide.The substance can be processed, for example, by an enzyme in a livingbody or through a process such as intracellular processing, and finallythe WT1 peptide becomes the form which can bind to any one of anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule. The substance may be a substance that modulates the solubilityof the WT1 peptide of the present invention, or increases its stability(resistance to protease, etc.). Alternatively, it may be a substancethat delivers the WT1 peptide of the present invention specifically, forexample, to a given tissue or organ, or increases the efficiency ofuptake by an antigen-presenting cell or the like. Alternatively, it maybe a WT1 peptide which is restricted to the same type of an MHC class Imolecule as that of a subject from which an antigen-presenting cell isderived.

The WT1 peptide of the present invention has an ability to bind to anyone of an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule andHLA-DPB1*0501 molecule. Thus, the WT1 peptide may be a peptide which hasan ability to bind to at least two of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule, or a peptide that hasan ability to bind to an HLA-DRB1*1501 molecule and/or HLA-DPB1*0901molecule and/or HLA-DPB1*0501 molecule, and an HLA class II moleculeother than the molecules, for example, a peptide which has an ability tobind to an HLA-DRB1*1501 molecule, HLA-DRB1*0405 molecule and/orHLA-DRB1*1502 molecule, a peptide which has an ability to bind to anHLA-DPB1*0901 molecule, HLA-DRB1*0405 molecule and/or HLA-DRB1*1502molecule, a peptide which has an ability to bind to an HLA-DPB1*0501molecule, HLA-DRB1*0405 molecule and/or HLA-DRB1*1502 molecule, or apeptide which has an ability to bind to an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule, HLA-DPB1*0501 molecule, HLA-DRB1*0405 moleculeand/or HLA-DRB1*1502 molecule. Because a WT1 peptide having an aminoacid sequence: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser ArgLys His (SEQ ID No: 2) has an ability to bind to an HLA-DRB1*1501molecule, an HLA-DPB1*0901 molecule, an HLA-DPB1*0501 molecule, anHLA-DRB1*0405 molecule and an HLA-DRB1*1502 molecule, the WT1 peptidehaving such an amino acid sequence is preferable. In general, an MHCclass II-binding peptide consists of 10-25 amino acids. Therefore, theWT1 peptide preferably has an amino acid sequence consisting of 10-25amino acids.

The WT1 peptide of the present invention can be synthesized by methodsgenerally used in the art or modifications thereof. Such methods aredescribed, for example, in Peptide Synthesis, Interscience, New York,1966; The Proteins, Vol 2, Academic Press Inc., New York, 1976;Peptide-Gosei, Maruzen Co., Ltd., 1975; Peptide-Gosei No Kiso To Jikken,Maruzen Co., Ltd., 1985; and Iyakuhin No Kaihatsu (Zoku), Vol. 14,Peptide-Gosei, Hirokawa—Book store, 1991.

The WT1 peptide of the present invention can also be prepared usinggenetic engineering techniques based on the information about thenucleotide sequence that encodes the WT1 peptide. Such geneticengineering techniques are well known to a person skilled in the art.

The antigen-presenting cell refers to a cell such as a dendritic cellwhich can present the WT1 peptide together with a MHC class II moleculeto a helper T cell or the like. Thus, a subject from which theantigen-presenting cell is derived must have the same subclass of MHCclass II (for example, HLA-DRB1*1501, HLA-DPB1*0901, HLA-DPB1*0501,HLA-DRB1*0405 or HLA-DRB1*1502) as that to which the added WT1 peptidebinds.

In general, a helper T cell is activated by the recognition of anantigen peptide through an MHC class II molecule on the surface of anantigen-presenting cell by TCR-CD3 complex on the surface of the T cell,and the stimulation of an integrin on the surface of the T cell by anintegrin ligand on the surface of the antigen-presenting cell. In thepresent invention, the activation of the helper T cell encompasses notonly the activation of the helper T cell but also the induction andgrowth of the helper T cell. As described above, the activated helper Tcell has a function to activate an immune system by increasing theinduction, growth or activation of a B cell or T cell. Thus, the methodfor the activation of a helper T cell of the present invention can beused as an adjuvant therapy in the treatment of a cancer or the like.Alternatively, the helper T cell activated in vitro using the method ofthe present invention can be used to treat or prevent a cancer or thelike, or can be used as an adjuvant therapy in the same. The activationof the helper T cell can be determined by measuring the amount of theproduction or secretion of a cytokine such as an interferon and aninterleukin, and the like.

The addition of the WT1 peptide to the antigen-presenting cell may bepracticed directly by the addition of the WT1 peptide, or indirectly bythe addition of an expression vector comprising a polynucleotideencoding the WT1 peptide or the addition of a cell comprising theexpression vector. The expression vector comprising the polynucleotideencoding the WT1 peptide, and the cell comprising the expression vectorcan be produced by the method well known to the person skilled in theart.

In another aspect, the present invention relates to a composition foractivating a helper T cell by the addition of a WT1 peptide to anantigen-presenting cell, comprising the WT1 peptide, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule. When the compositionof the present invention is administered to an HLA-DRB1*1501,HLA-DPB1*0901 or HLA-DPB1*0501-positive subject, an immune system in thesubject is activated by the activation of the helper T cell in thesubject. The WT1 gene is expressed at high levels in various cancers andtumors including hematopoietic tumors such as leukemia, myelodysplasticsyndrome, multiple myeloma or malignant lymphoma, and solid cancers suchas gastric cancer, colon cancer, lung cancer, breast cancer, germ cellcancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer,uterine cancer, cervical cancer or ovarian cancer. Therefore, thecomposition of the present invention can be used as an adjuvant therapyin the treatment or prevention of a cancer. Alternatively, the helper Tcell activated using the composition of the present invention can beused, for example, as an adjuvant in the treatment of a cancer.

As described above, the WT1 peptide of the present invention may be apeptide which has an ability to bind to at least two of an HLA-DRB1*1501molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule, or apeptide which has an ability to bind to an HLA-DRB1*1501 molecule and/orHLA-DPB1*0901 molecule and/or HLA-DPB1*0501 molecule, and an MHC classII molecule other than them. Thus, as long as the antigen-presentingcell is derived from a subject positive for an MHC class II subclass towhich the WT1 peptide of the present invention can bind, the effect ofactivating the helper T cell of the composition of the present inventioncan result.

The composition of the present invention may comprise in addition to theWT1 peptide, for example, a carrier, an excipient, an additive or thelike. Because the WT1 peptide comprised in the composition of thepresent invention activate the helper peptide specifically to the WT1peptide, the composition may comprise an MHC class I-restricted WT1peptide, or it may be used with the peptide.

The method for using the composition of the present invention can beappropriately selected depending on conditions such as the desiredactivation of the helper T cell, the state of the antigen-presentingcell. Examples of such methods include, but are not limited to,intradermal administration, subcutaneous administration, intramuscularadministration, intravenous administration, nasal administration andoral administration, and the addition to a culture medium of theantigen-presenting cell. The amount of the WT1 peptide comprised in thecomposition of the present invention, as well as the form, the number oftimes of use the like of the composition of the present invention can beappropriately selected depending on conditions such as the desiredactivation of the helper T cell, the state of the antigen-presentingcell.

In a further aspect, the present invention relates to a composition foractivating a helper T cell by the addition of a WT1 peptide to anantigen-presenting cell, comprising an expression vector comprising apolynucleotide encoding the WT1 peptide or a cell comprising theexpression vector, wherein the WT1 peptide has an ability to bind to anyone of an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule andHLA-DPB1*0501 molecule. The expression vector comprising thepolynucleotide encoding the WT1 peptide and the cell comprising theexpression vector are described above.

In another aspect, the present invention relate to use of an expressionvector comprising a polynucleotide encoding a WT1 peptide, or a cellcomprising the expression vector for the manufacture of the composition.

In a further aspect, the present invention relates to a kit foractivating a helper T cell by the addition of a WT1 peptide to anantigen-presenting cell, comprising the WT1 peptide, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule. Preferably, the kitis used in the method for the activation of a helper T cell. The kit ofthe present invention may comprise in addition to the WT1 peptide, forexample, a means of obtaining an antigen-presenting cell, a means todetermine a helper T cell activity or the like. In general, aninstruction manual is attached to the kit. By using the kit of thepresent invention, helper T cells can be induced efficiently.

In another aspect, the present invention relates to a kit for activatinga helper T cell by the addition of a WT1 peptide to anantigen-presenting cell, comprising an expression vector comprising apolynucleotide encoding WT1 peptide, or a cell comprising the expressionvector, wherein the WT1 peptide has an ability to bind to any one of anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule.

In another aspect, the present invention relates to a method for thetreatment or prevention of a cancer in a subject, comprising adding aWT1 peptide to an antigen-presenting cell, and thereby activating ahelper T cell, wherein the WT1 peptide has an ability to bind to any oneof an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule. The method of the present invention is a method in which animmune system in the subject is activated by the activation of a helperT cell, and a cancer in the subject is treated or prevented. Theaddition of the WT1 peptide to the antigen-presenting cell may bepracticed directly by the addition of the WT1 peptide, or indirectly bythe addition of an expression vector comprising a polynucleotideencoding the WT1 peptide or the addition of a cell comprising theexpression vector.

As described above, the helper T cell recognizes the complex of any oneof MHC class II molecules, particularly an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule and the WT1 peptide.Therefore, the subject is a subject having an MHC class II molecule towhich the WT1 peptide binds, for example, HLA-DRB1*1501-positive,HLA-DPB1*0901-positive or HLA-DPB1*0501-positive subject. As describedabove, the WT1 peptide of the present invention may be a peptide whichhas an ability to bind to at least two of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule, or a peptide whichhas an ability to bind to an HLA-DRB1*1501 molecule and/or HLA-DPB1*0901molecule and/or HLA-DPB1*0501 molecule, and an MHC class II moleculeother than them. Thus, in such a case, it is possible to treat orprevent a cancer in a subject positive for an MHC class II subclass towhich the WT1 peptide of the present invention can bind. The cancer tobe treated or prevented may be any one, and examples thereof includehematopoietic tumors such as leukemia, myelodysplastic syndrome,multiple myeloma or malignant lymphoma, and solid cancers such asgastric cancer, colon cancer, lung cancer, breast cancer, germ cellcancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer,uterine cancer, cervical cancer or ovarian cancer. Furthermore, themethod of the present invention may be used with a method for thetreatment or prevention of a cancer with an MHC class Imolecule-restricted WT1 peptide or a pharmaceutical composition for thesame.

In another aspect, the present invention relates to a pharmaceuticalcomposition for the treatment or prevention of a cancer in a subject byactivating a helper T cell by the addition of a WT1 peptide to anantigen-presenting cell, comprising the WT1 peptide, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule. The WT1 gene isexpressed at high levels in various cancers and tumors includinghematopoietic tumors such as leukemia, myelodysplastic syndrome,multiple myeloma or malignant lymphoma, and solid cancers such asgastric cancer, colon cancer, lung cancer, breast cancer, germ cellcancer, hepatic cancer, skin cancer, bladder cancer, prostate cancer,uterine cancer, cervical cancer or ovarian cancer. Therefore, thepharmaceutical composition of the present invention can be used for thetreatment or prevention of a cancer.

As described above, the WT1 peptide of the present invention may be apeptide which has an ability to bind to at least two of an HLA-DRB1*1501molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule, or apeptide which has an ability to bind to an HLA-DRB1*1501 molecule and/orHLA-DPB1*0901 molecule and/or HLA-DPB1*0501 molecule, and an MHC classII molecule other than them. Thus, as long as the antigen-presentingcell is derived from a subject positive for an MHC class II subclass towhich the WT1 peptide of the present invention can bind, thepharmaceutical composition of the present invention can be used to treator prevent a cancer.

When the pharmaceutical composition of the present invention isadministered to, for example, an HLA-DRB1*1501-positive,HLA-DPB1*0901-positive or HLA-DPB1*0501-positive subject, an immunesystem in a subject can be activated by the activation of the helper Tcell by the WT1 peptide comprised in the pharmaceutical composition,thereby treating or preventing a cancer. Thus, the pharmaceuticalcomposition of the present invention may be used together with themethod for the treatment or prevention of a cancer or the pharmaceuticalcomposition for the same.

The pharmaceutical composition of the present invention may comprise inaddition to the WT1 peptide as an active ingredient, for example, acarrier, an excipient or the like. The WT1 peptide comprised in thepharmaceutical composition of the present invention binds to an MHCclass II molecule on the surface of an antigen-presenting cell andactivates a helper T cell. Therefore, the pharmaceutical composition ofthe present invention may further comprise an activator, growth factor,inducer or the like of the helper T cell, or may comprise an MHC classI-restricted WT1 peptide.

The method for administering the pharmaceutical composition of thepresent invention can be appropriately selected depending on conditionssuch as the type of disease, the condition of the subject or targetsite. Examples of such methods include, but are not limited to,intradermal administration, subcutaneous administration, intramuscularadministration, intravenous administration, nasal administration andoral administration. The amount of the peptide comprised in thepharmaceutical composition of the present invention, as well as thedosage form, the number of times of the administration and the like ofthe pharmaceutical composition of the present invention can beappropriately selected depending on conditions such as the type ofdisease, the condition of the subject or the target site. The singledose of the peptide is usually, 0.0001 mg-1000 mg, preferably, 0.001mg-1000 mg.

In a further aspect, the present invention relates to a pharmaceuticalcomposition for the treatment or prevention of a cancer in a subject byactivating a helper T cell by the addition of a WT1 peptide to anantigen-presenting cell, comprising an expression vector comprising apolynucleotide encoding the WT1 peptide, or a cell comprising theexpression vector, wherein the WT1 peptide has an ability to bind to anyone of an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule andHLA-DPB1*0501 molecule.

In a further aspect, the present invention relates to use of a WT1peptide, an expression vector comprising a polynucleotide encoding theWT1 peptide, or a cell comprising the expression vector for themanufacture of the pharmaceutical composition.

In another aspect, the present invention relates to an antibody bindingspecifically to a WT1 peptide, wherein the WT1 peptide has an ability tobind to any one of an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 moleculeand HLA-DPB1*0501 molecule. The antibody of the present invention can beprepared by the means or method known to the person skilled in the art.The antibody of the present invention can be used for the diagnosis ofvarious cancers, prognosis thereof or the like.

In another aspect, the present invention relates to a method for thedetermination of the presence or amount of a WT1 peptide in anHLA-DRB1*1501-positive, HLA-DPB1*0901-positive or HLA-DPB1*0501-positivesubject, comprising:

(a) reacting an anti-WT1 antibody with a sample form the subject; and(b) determining the presence or amount of the anti-WT1 antibody bindingspecifically to the WT1 peptide contained in the sample. For example, itis possible to diagnose a cancer, prognosis thereof or the like byincubating the anti-WT1 antibody with a sample from anHLA-DRB1*1501-positive, HLA-DPB1*0901-positive or HLA-DPB1*0501-positivesubject, or administering the anti-WT1 antibody to anHLA-DRB1*1501-positive, HLA-DPB1*0901-positive or HLA-DPB1*0501-positivesubject, and determining, for example, the position, site or amountthereof. The anti-WT1 antibody of the present invention refers to anantibody which can specifically recognize the WT1 peptide of the presentinvention. The anti-WT1 antibody may be a monoclonal antibody orpolyclonal antibody. The anti-WT1 antibody may be labeled. A known labelsuch as a fluorescent label or a radioactive label can be used as alabel. By labeling it, the presence or amount of the WT1 peptide can bedetermined readily and rapidly.

In another aspect, the present invention relates to a kit for thedetermination of the presence or amount of a WT1 peptide comprising theanti-WT1 antibody as an essential component.

Furthermore, in the determination of the presence or amount of the WT1peptide, when the WT1 peptide has an ability to bind to an HLA-DRB1*0405molecule and/or HLA-DRB1*1502 molecule, it is possible to determine thepresence or amount of the WT1 peptide in a subject with such an MHCclass II subclass.

In another aspect, the present invention relates to a pharmaceuticalcomposition for the treatment or prevention of a cancer, comprising ahelper T cell activated with a WT1 peptide, wherein the WT1 peptide hasan ability to bind to an any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule. The cancer is treatedor prevented by the induction, growth or activation of a B cell or Tcell by the activated helper T cell. Thus, the pharmaceuticalcomposition of the present invention in this aspect may be used togetherwith another method for the treatment or prevention of a cancer orpharmaceutical composition for the same. The activation of the helper Tcell with the WT1 peptide encompasses not only the direct activationwith the WT1 peptide but also indirect activation with an expressionvector comprising a polynucleotide encoding the WT1 peptide or a cellcomprising the expression vector.

The pharmaceutical composition of the present invention may comprise inaddition to the activated helper T cell as an active ingredient, forexample, a carrier, an excipient or the like. The method foradministering the pharmaceutical composition of the present inventioncan be appropriately selected depending on conditions such as the typeof disease, the condition of the subject or the target site. Examples ofsuch methods include, but are not limited to, intradermaladministration, subcutaneous administration, intramuscularadministration, intravenous administration, nasal administration andoral administration. The amount of the helper T cell comprised in thepharmaceutical composition of the present invention, as well as thedosage form, the number of times of the administration and the like ofthe pharmaceutical composition of the present invention can beappropriately selected depending on a condition such as the type ofdisease, the condition of the subject or the target site.

In another aspect, the present invention relates to a method for thetreatment or prevention of a cancer, comprising adding a WT1 peptide toan antigen-presenting cell, and thereby activating a helper T cell, andadministering the activated helper T cell to a subject, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule.

In another aspect, the present invention relates to use of a WT1 peptidefor the manufacture of the pharmaceutical composition comprising anactivated helper T cell.

In a further aspect, the present invention relates to a method for thedetermining the presence or amount of a WT1-specific helper T cell inany one of an HLA-DRB1*1501-positive, HLA-DPB1*0901-positive andHLA-DPB1*0501-positive subject, comprising:

(a) reacting a complex of a WT1 peptide and an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule with a sample from thesubject; and(b) determining the presence or amount of a helper T cell recognizingthe complex contained in the sample. The sample from the subject may beany one as long as there is a possibility that it contains a lymphocyte.Examples of the samples include body fluid such as blood or lymph and atissue. The complex of a WT1 peptide and an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule may be prepared, forexample, as a tetramer or pentamer using a method known to a personskilled in the art such as biotin-streptavidin method. The presence oramount of the helper T cell recognizing such a complex can be measuredby a method known to a person skilled in the art. In this aspect of thepresent invention, the complex may be labeled. A known label such as afluorescent label or a radioactive label can be used as a label. Bylabeling it, the presence or amount of the helper T cell can be rapidlyor readily determined. The method of the present invention in thisaspect can be used to diagnose a cancer, prognosis thereof or the like.

Thus, the present invention also provides composition for thedetermination of the presence or amount of a helper T cell in any one ofan HLA-DRB1*1501-positive, HLA-DPB1*0901-positive andHLA-DPB1*0501-positive subject, comprising a complex of a WT1 peptideand an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501molecule.

Furthermore, the present invention provides a kit for the determinationof the presence or amount of a helper T cell in anHLA-DRB1*1501-positive, HLA-DPB1*0901-positive or HLA-DPB1*0501-positivesubject, comprising a complex of a WT1 peptide and an HLA-DRB1*1501molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule.

Furthermore, in the determination of the presence or amount of thehelper T cell, when the WT1 peptide has an ability to an HLA-DRB1*0405molecule and/or HLA-DRB1*1502 molecule in the determination of thepresence or amount of the helper T cell, it is possible to determine thepresence or amount of the helper T cell in a subject with such an MHCclass II subclass. In such a case, a complex of a WT1 peptide and a MHCclass II molecule to which the WT1 peptide binds is used.

In a further aspect, the present invention relates to a method for theobtainment of a helper T cell using a complex of a WT1 peptide and anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501molecule, comprising:

(a) reacting a sample with the complex; and(b) obtaining a helper T cell recognizing the complex contained in thesample. The complex is described above. The sample may be any one aslong as there is a possibility that it contains a lymphocyte. Examplesof the samples include a sample from a subject such as blood, and a cellculture. The helper T cell recognizing the complex can be obtained usinga method known to a person skilled in the art such as FACS or MACS. Thepresent invention allows to culture the obtained helper T cell and useit for the treatment or prevention of various cancers.

Thus, the present invention also relates to a helper T cell which isobtainable by a method for obtaining a helper T cell using a complex ofa WT1 peptide and an HLA-DRB1*1501 molecule, HLA-DPB1*0901: molecule orHLA-DPB1*0501 molecule.

Furthermore, the present invention relates to a kit for obtaining ahelper T cell, comprising a complex of a WT1 peptide and anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501molecule.

Furthermore, in obtaining the helper T cell, when the WT1 peptide has anability to bind to an HLA-DRB1*0405 molecule and/or HLA-DRB1*1502molecule, it is possible to obtain a helper T cell recognizing a complexof such an MHC class II subclass and a WT1 peptide. In such a case, thecomplex of the WT1 peptide and an MHC class II molecule to which itbinds is used.

In another aspect, the present invention relates to a method for thedetermination of the presence or amount of a WT1-specific helper T cellin an HLA-DRB1*1501-positive, HLA-DPB1*0901-positive,HLA-DPB1*0501-positive, HLA-DRB1*0405-positive or HLA-DRB1*1502-positivesubject, comprising:

(a) stimulating a peripheral blood mononuclear cell, invasivelymphocyte, tumor cell, cell in ascitic fluid, cell in pleural fluid,cell in cerebrospinal fluid, bone marrow cell or lymph node cell with aWT1 peptide; and(b) determining the production of a cytokine or the reaction of thehelper T cell,wherein a presence or an increase in the amount of the production of thecytokine or the reaction of the helper T cell indicates the presence oramount of the WT1-specific helper T cell. The cells such as theperipheral blood mononuclear cell, invasive lymphocyte, tumor cell, cellin ascitic fluid, cell in pleural fluid, cell in cerebrospinal fluid,bone marrow cell and lymph node cell used in the method of the presentinvention may be derived from a healthy subject or a cancer patient. Byusing the cells from a healthy subject, it is possible to determinewhether or not the subject is suffering from a cancer, whether or notthe subject has the predisposition thereof or the like. By using thecells from a cancer patient, it is possible to predict whether or notWT1-immunnotherapy has a effect on the cancer patient or the like. Thestimulation of the cells with the WT1 peptide may be practiced in vitroor in vivo. Because of easiness, in vitro stimulation is preferable. Thepresence of the production of the cytokine or the reaction of the helperT cell, or the amount of the production of the cytokine or the reactionof the helper T cell can be determined by a known method.

The following examples illustrate the present invention in more detail,but are not to be construed to limit the scope thereof.

Examples 1. Preparation of Antigen-Presenting Cell

Peripheral blood mononuclear cells (PBMCs) were separated fromperipheral blood that had been collected from a healthy donor(HLA-DRB1*1501-positive, HLA-DPB1*0901-positive orHLA-DPB1*0501-positive). The PBMCs were seeded to a 6-well plastic plateat the density of 1×10⁷ cells/well in 1% AB serum (Nabi, Miami, Fla.),X-VIVO 15 medium (Cambrex), and cultured for 2 hours. After the culture,suspension cells were removed, and the remaining adherent cells werecultured in 1000 IU/ml IL-4 (PeproTech), 1000 IU/ml GM-CSF (PeproTech),1% AB serum and X-VIVO 15 medium. On day 2 and day 4, the medium waschanged, and IL-4 and GM-CSF were added. On day 6, 100 IU/ml TNF-α wasadded to mature antigen-presenting cells.

2. Induction of WT1 Peptide-specific CD4-Positive T Cell

CD4-positive T cells were separated from blood derived from the samedonor using RosetteSep for the separation of CD4-positive T cells(StemCell). The CD4-positive T cells (3×10⁶ cells) were added to eachwell of a 24-well plate. They were stimulated with autologousantigen-presenting cells (3×10⁵ cells) that had been pulsed with 20μg/ml WT1 peptide (SEQ ID No: 2), and irradiated with 25 Gy ofradiation. On next day after the stimulation, 20 IU/ml IL-2 was added.Likewise, the stimulated CD4-positive T cells were stimulated using theantigen-presenting cells pulsed with 20 μg/ml WT1 peptide every otherweek. Furthermore, the medium was changed to the medium containing IL-2every other day after second stimulation. The CD4-positive T cellsinduced by total three times of stimulation (HLA-DRB1*1501 andHLA-DPB1*0901-positive T cells were defined as TA28.1 cell and E15.2cell, respectively) were used for experiments below.

3. Measurement of IFN-γ

TA28.1 cells and peripheral blood mononuclear cells from a subject fromwhich the TA28.1 cells were derived were cultured in the presence of 20μg/ml WT1 peptide for 24 hours. After the culture, the amount of IFN-γin the supernatant was quantified using ELISA kit. As a control, aperipheral blood mononuclear cell from an HLA-DRB1*1501-negative subjectwas used. The results are shown in FIG. 1. It was confirmed that TA28.1cell recognizes the WT1 peptide specifically to an HLA-DRB1*1501molecule to increase the produced amount of IFN-γ (that is, activation).

Furthermore, it was confirmed that TA28.1 cell and E15.2 cell do notproduce IL-4 and IL-10 using ELISA kit. The results are shown in FIGS. 2and 3. It was confirmed that TA28.1 and E15.2 cell are Th1 cells.

HLA-DPB1*0501/*0501-positive mononuclear cells were used to perform thefollowing experiments. The cells were suspended to X-VIVO (1% AB serum),and 20 μg/ml WT1 peptide, 10 μg/ml Brefeldin A and 0.5 μg/ml CD28/49dwere added. They were incubated at 37° C. with 5% CO₂ for 4 hours. AS acontrol, a cell incubated without the addition of WT1 peptide was used.After washing with buffer, an anti-CD3-perCP antibody and ananti-CD4-APC antibody were added, and they were incubated at 4° C. for30 minutes. After washing with buffer, the cells were fixed andpermeabilized using BD Cytofix/Cytoperm (4° C., 20 minutes). Afterwashing with BD perm/wash buffer, an anti-INF-γ-FITC (BD, clone: B27)and anti-IL-17-PE (eBioscience, clone: eBio64DEC17) were added, and theywere incubated at 4° C. for 30 minutes. After washing with buffer, cellswere analyzed with FACSAria. The results are shown in FIG. 4. It wasconfirmed that an HLA-DPB1*0501-positive mononuclear cells grow, andproduces IFN-γ and IL-17.

4. Growth Assay

The growth assay was performed by [³H]-thymidine incorporation method.TA28.1 cells (3×10⁴ cells) and peripheral blood mononuclear cells(HLA-DRB1*1501-positive; 1×10⁵ cells) that had been pulsed with the WT1peptides and irradiated were cocultured in a 96-well plate. Aftercoculturing for 80 hours, 37 kBq/well [³H]-thymidine (AmershamBiosciences) was added. They were incubated for another 16 hours, andmeasured using β-scintillation counter. The measurements wererepresented as count/minute (cpm). As a control, a peripheral bloodmononuclear cell without pulsing with a peptide was used. Furthermore,in order to confirm that the activation signal is specific for anHLA-DRB1*1501 molecule, an anti-MHC class I antibody, anti-HLA-DRantibody, anti-HLA-DQ antibody and anti-HLA-DP antibody were used. Theresults are shown in FIG. 5. It was confirmed that TA28.1 cells wereactivated by a signal through the WT1 peptide and HLA-DRB1*1501, andgrown. It was further confirmed that the growth was specific forHLA-DRB1*1501, because it was suppressed by the anti-HLA-DR antibody.

Likewise, E15.2 cells were used to perform the growth assay. As anadditional control, the peripheral blood mononuclear cells from anHLA-DPB1*0901-negative subject were used. The results are shown in FIGS.6 and 7. It was confirmed that E15.2 cells were activated by a signalthrough the WT1 peptide and HLA-DPB1*0901, and grown. It was furtherconfirmed that the growth is specific for HLA-DPB1*0901, because it issuppressed by the anti-HLA-DP antibody.

Furthermore, HLA-DPB1*0501/*0501-positive mononuclear cells were used toperform the growth assay. As a control, a peripheral blood mononuclearcell from an HLA-DPB1*0501-negative subject was also used. The resultsare shown in FIGS. 8 and 9. It was confirmed that anHLA-DPB1*0501/*0501-positive mononuclear cells were activated by asignal through the WT1 peptide and HLA-DPB1*0501, and grown. It wasfurther confirmed that the growth is specific for HLA-DPB1*0501, becauseit is suppressed by the anti-HLA-DP antibody.

Furthermore, the growth assay of the E15.2 cells was performed withvarious concentrations of the WT1 peptide. The concentration of the usedWT1 peptide was 0.08, 0.4, 2, 10, 50, 100 or 150 μg/ml. The results areshown in FIG. 10. It was confirmed that the WT1 peptides grow the E15.2cells in a concentration-dependent manner.

INDUSTRIAL APPLICABILITY

The present invention provides a method for the activation of a helper Tcell with a WT1 peptide which has an ability to bind to an HLA-DRB1*1501molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule and acomposition for the same, as well as a pharmaceutical composition forthe treatment and/or prevention of a cancer by activating a helper Tcell and the like. Therefore, the present invention can be used in thefields of medicine and the like, for example, in the fields ofdevelopment and preparation of a pharmaceutical composition for theprevention or treatment of various hematopoietic tumors and solidcancers that express WT1 gene at high levels.

1. A method for the activation of a helper T cell, comprising adding aWT1 peptide to an antigen-presenting cell, and thereby activating thehelper T cell, wherein the WT1 peptide has an ability to bind to any oneof an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule.
 2. The method according to claim 1, wherein the WT1 peptidehas an ability to bind to at least two of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule.
 3. The methodaccording to claim 1 or 2, wherein the WT1 peptide further has anability to bind to an HLA-DRB1*0405 molecule and/or HLA-DRB1*1502molecule.
 4. The method according to any one of claims 1-3, wherein theWT1 peptide has an ability to bind to an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule, HLA-DPB1*0501 molecule, HLA-DRB1*0405 moleculeand HLA-DRB1*1502 molecule.
 5. The method according to any one of claims1-4, wherein the WT1 peptide is a peptide comprising an amino acidsequence: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg LysHis (SEQ ID No: 2).
 6. The method according to any one of claims 1-5,wherein the addition of the WT1 peptide to the antigen-presenting cellis practiced by the addition of the WT1 peptide, the addition of anexpression vector comprising the polynucleotide encoding the WT1 peptideor the addition of a cell including the expression vector.
 7. Acomposition for activating a helper T cell by the addition of a WT1peptide to an antigen-presenting cell, comprising the WT1 peptide,wherein the WT1 peptide has an ability to bind to any one of anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule.
 8. A method for the treatment or prevention of a cancer in asubject, comprising adding a WT1 peptide to an antigen-presenting cell,and thereby activating a helper T cell, wherein the WT1 peptide has anability to bind to any one of an HLA-DRB1*1501 molecule, HLA-DPB1*0901molecule and HLA-DPB1*0501 molecule.
 9. A pharmaceutical composition forthe treatment or prevention of a cancer by activating a helper T cell bythe addition of a WT1 peptide to an antigen-presenting cell, comprisingthe WT1 peptide, wherein the WT1 peptide has an ability to bind to anyone of an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule andHLA-DPB1*0501 molecule.
 10. An antibody binding specifically to a WT1peptide, wherein the WT1 peptide has an ability to bind to any one of anHLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule and HLA-DPB1*0501molecule.
 11. A method for the determination of the presence or amountof a WT1 peptide in any on a of an HLA-DRB1*1501-positive,HLA-DPB1*0901-positive and HLA-DPB1*0501-positive subject, comprising:(a) reacting an anti-WT1 antibody with a sample from the subject; and(b) determining the presence or amount of the anti-WT1 antibody bindingspecifically to the WT1 peptide contained in the sample.
 12. A methodfor the treatment or prevention of a cancer, comprising adding a WT1peptide to an antigen-presenting cell, and thereby activating a helper Tcell, and administering the activated helper T cell to a subject,wherein the WT1 peptide has an ability to bind to an HLA-DRB1*1501molecule, HLA-DPB1*0901 molecule or HLA-DPB1*0501 molecule.
 13. Apharmaceutical composition for the treatment or prevention of a cancer,comprising a helper T cell activated with a WT1 peptide, wherein the WT1peptide has an ability to bind to any one of an HLA-DRB1*1501 molecule,HLA-DPB1*0901 molecule and HLA-DPB1*0501 molecule.
 14. A method for thedetermination of the presence or amount of a WT1-specific helper T cellin any one of an HLA-DRB1*1501-positive, HLA-DPB1*0901-positive andHLA-DPB1*0501-positive subject, comprising: (a) reacting a complex of aWT1 peptide and an HLA-DRB1*1501 molecule, HLA-DPB1*0901 molecule orHLA-DPB1*0501 molecule with a sample from the subject; and (b)determining the presence or amount of a helper T cell recognizing thecomplex contained in the sample.
 15. A method for the determination ofthe presence or amount of a WT1-specific helper T cell in anHLA-DRB1*1501-positive, HLA-DPB1*0901-positive, HLA-DPB1*0501-positive,HLA-DRB1*0405-positive or HLA-DRB1*1502-positive subject, comprising:(a) stimulating a peripheral blood mononuclear cell, invasivelymphocyte, tumor cell, cell in ascitic fluid, cell in pleural fluid,cell in cerebrospinal fluid, bone marrow cell or lymph node cell with aWT1 peptide; and (b) determining the production of a cytokine or thereaction of the helper T cell, wherein a presence or an increase in theamount of the production of the cytokine or the reaction of the helper Tcell indicates the presence or amount of the WT1-specific helper T cell.